

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10511537
	Filing Date		2004-10-15
	First Named Inventor	Hanson	
	Art Unit	1624	
	Examiner Name	Mark L. Berch	
	Attorney Docket Number	100647-1P US	

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5716967		1998-02-10	Kleinman	
	2	5976823		1999-11-02	Wu	
	3	6046019		2000-04-04	Goumeniouk et al.	
	4	6294541		2001-09-25	Cavalla et al.	

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20040022871		2004-02-05	Mainnemare	
	2	20040029871		2004-02-12	Kettle et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10511537
Filing Date		2004-10-15
First Named Inventor	Hanson	
Art Unit	1624	
Examiner Name	Mark L. Berch	
Attorney Docket Number	100647-1P US	

	3	20070032468		2007-02-08	Kettle et al.	
--	---	-------------	--	------------	---------------	--

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	1013676	CN		1991-08-28	Euroceltique S.A.		<input checked="" type="checkbox"/>
	2	9917773	WO	A1	1999-04-15	Smithkline Beecham Corporation		<input type="checkbox"/>
	3	0051598	WO	A1	2000-09-08	Smithkline Beecham Corporation		<input type="checkbox"/>
	4	0208237	WO	A2	2002-01-31	Lyles, Mark B.		<input type="checkbox"/>
	5	02090575	WO	A1	2002-11-14	AstraZeneca AB		<input type="checkbox"/>
	6	2005037835	WO	A1	2005-04-28	AstraZeneca AB		<input type="checkbox"/>
	7	2005077950	WO	A2	2005-08-25	Smithkline Beecham Corporation		<input type="checkbox"/>
	8	2006045564	WO	A1	2006-05-04	Smithkline Beecham Corporation		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10511537
Filing Date	2004-10-15
First Named Inventor	Hanson
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	100647-1P US

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	
	1	AARON, S D et al., "Granulocyte Inflammatory Markers and Airway Infection during Acute Exacerbation of Chronic Obstructive Pulmonary Disease," Am J Respir Crit Care Med., 2001, pgs. 349-355, vol. 163	<input type="checkbox"/>	
	2	AKBIYIK et al., "In vitro and in vivo inhibition of myeloperoxidase with 5-fluorouracil," Eur. J. Clin. Pharmacol., 2001, Vol. 57, pgs. 631-636	<input type="checkbox"/>	
	3	BALDUS, S. et al., "Myeloperoxidase Serum Levels Predict Risk in Patients with Acute Coronary Syndromes," Circulation, 2003, pgs. 1440-1445, vol. 108	<input type="checkbox"/>	
	4	BERLOW et al., "The Effect of Dapsone in Steroid-Dependent Asthma," 1991, J. Allergy Clin. Immunol., 1991, Vol. 87 (3), pgs. 710-715	<input type="checkbox"/>	
	5	BOZEMAN et al., "Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone," Biochemical Pharmacology, 1992, Vol. 44, No. 3, pgs. 553-563	<input type="checkbox"/>	
	6	BRENNAN, M. et al., "Prognostic Value of Myeloperoxidase in Patients with Chest Pain," N Engl J Med., 2003, pgs 1595-1604, vol. 349, no. 17	<input type="checkbox"/>	
	7	CHOI, D-K et al., "Ablation of the Inflammatory Enzyme Myeloperoxidase Mitigates Features of Parkinson's Disease in Mice," J. Neurosci., 2005, pgs. 6594-6600, vol. 25, no. 28	<input type="checkbox"/>	
	8	CROOKS, S W et al., "Bronchial Inflammation in Acute Bacterial Exacerbations of Chronic Bronchitis: the Role of Leukotriene B4," European Respiratory Journal, 2000, pgs. 274-280, vol. 15, no. 2	<input type="checkbox"/>	
	9	CUZNER, M L et al., "Plasminogen Activators and Matrix Metalloproteases, Mediators of Extracellular Proteolysis in Inflammatory Demyelination of the Central Nervous System," Journal of Neuroimmunology, 1999, pgs. 1-14, vol. 94, no. 1-2	<input type="checkbox"/>	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10511537
Filing Date		2004-10-15
First Named Inventor	Hanson	
Art Unit	1624	
Examiner Name	Mark L. Berch	
Attorney Docket Number	100647-1P US	

10	DALLEGRI et al., Possible Modes of Action of Nimesulide in Controlling Neutrophilic Inflammation," Arzneimittel-Forschung/Drug Research, 1995, Vol. 45(II), No. 10, pgs. 1114-1117	<input type="checkbox"/>
11	DAUGHERTY, A. et al., "Myeloperoxidase, a Catalyst for Lipoprotein Oxidation, Is Expressed in Human Atherosclerotic Lesions," J Clin Invest., 1994, pgs. 437-444, vol. 94, no. 1	<input type="checkbox"/>
12	FIORINI, G. et al., "Serum ECP and MPO are Increased During Exacerbations of Chronic Bronchitis with Airway Obstruction," Biomedicine & Pharmacotherapy, 2000, pgs. 274-278, vol. 54	<input type="checkbox"/>
13	GREEN, P S et al., "Neuronal Expression of Myeloperoxidase is Increased in Alzheimer's Disease," Journal of Neurochemistry, 2004, pgs. 724-733, vol. 90, no. 3	<input type="checkbox"/>
14	GRISHAM et al., "Assessment of Leukocyte involvement during Ischemia and Reperfusion of Intestine," Am. J. Physiol., 1986, Vol. 251, pgs. 729-742	<input type="checkbox"/>
15	HAMPTON, M B, et al., "Inside the Neutrophil Phagosome: Oxidants, Myeloperoxidase, and Bacterial Killing," Blood, 1998, pgs. 3007-3017, vol. 92, no. 9	<input type="checkbox"/>
16	HOPE et al., "Large scale purification of myeloperoxidase from HL60 promyelocytic cells: characterization and comparison to human neutrophil myeloperoxidase," Protein Expression and Purification, 2000, Vol. 18, pgs. 269-276	<input type="checkbox"/>
17	KETTLE et al., "Assays for the Chlorination Activity of Myeloperoxidase," Biophys, 1992, Vol. 296, pgs. 502-512	<input type="checkbox"/>
18	KETTLE et al., "Mechanism of inhibition of myeloperoxidase by anti-inflammatory drugs," Biochemical Pharmacology, 1991, Vol. 41, No. 10, pgs. 1485-1492	<input type="checkbox"/>
19	KETTLE et al., "Superoxide is an Antagonist of Anti-Inflammatory Drugs that Inhibit Hypochlorous Acid Production by Myeloperoxidase," Biochemical Pharmacology, 1993, Vol. 45, No. 10, pgs. 2003-2010	<input type="checkbox"/>
20	Khimicheskaya encyclopedia, ed. by Knunyants I.L., "Sovetskaya encyclopedia", 1990, V. 2, pg. 1083	<input checked="" type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10511537
Filing Date	2004-10-15
First Named Inventor	Hanson
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	100647-1P US

21	KUTTER, D. et al., "Consequences of Total and Subtotal Myeloperoxidase Deficiency: Risk or Benefit?," Acta Haematol, 2000, pgs. 10-15, vol. 104, no. 1	<input type="checkbox"/>
22	LECKIE et al., "Novel Therapy for COPD," Exp. Opin. Invest. Drugs, 2000, Vol. 9(1), pgs. 3-23	<input type="checkbox"/>
23	MARTIN et al., "Reduction of Neutrophil-mediated injury to pulmonary endothelial cells by Dapsone 1-3", Am. Rev. Respir Dis., 1985, Vol. 131, pgs. 544-547	<input type="checkbox"/>
24	NAGRA, R M, et al., "Immunohistochemical and Genetic Evidence of Myeloperoxidase Involvement in Multiple Sclerosis," Journal of Neuroimmunology, 1997, pgs 97-107, vol 78, no. 1-2	<input type="checkbox"/>
25	NOCKER et al., "Interleukin-8 in Airway Inflammation in Patients with Chronic Asthma and Chronic Obstructive Pulmonary Disease," Int. Arch Allergy Immunol., 1996, Vol. 109, pgs. 183-191	<input type="checkbox"/>
26	OTTONELLO et al., "Sulphonamides as Anti-Inflammatory Agents: Old Drugs for New Therapeutic Strategies in Neutrophilic Inflammation," Clinical Science, 1995, Vol. 88, pgs. 331-336	<input type="checkbox"/>
27	SUGIYAMA, S. et al., "Macrophage Myeloperoxidase Regulation by Granulocyte Macrophage Colony-Stimulating Factor in Human Atherosclerosis and Implications in Acute Coronary Syndromes," Am J Pathol, 2001, pgs. 879-891, vol. 158, no. 3	<input type="checkbox"/>
28	SUZUKI et al., "Assay method for myeloperoxidase in human polymorphonuclear leukocytes," Analytical Biochemistry, 1983, Vol. 132, pgs. 345-352	<input type="checkbox"/>
29	VAN ZYL et al., "Interaction of methylxanthines with myeloperoxidase. An anti-inflammatory mechanism," Intl J. of Biochem, 1992, Vol. 24(6), pgs. 929-935	<input type="checkbox"/>
30	ZHANG, R. et al., " Association Between Myeloperoxidase Levels and Risk of Coronary Artery Disease," Jama, 2001, pgs. 2136-2142, vol. 286, no. 17	<input type="checkbox"/>
31	STN Intl, CAPLUS Accession No. 1968:434597, Doc No. 69:34597, Dietz et al., "The hypnotic properties of 8-ethylthio-6-thiotheophylline sodium" & Toxicology and Applied Pharm., 1968, Vol. 12, pgs. 202-6	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10511537
Filing Date	2004-10-15
First Named Inventor	Hanson
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	100647-1P US

32	STN Intl, CAPLUS Accession No. 1966:420839, Doc No. 65:20839, Dietz et al., "The synthesis and pharmacologic evaluation of a series of 8-alkylthio-thiated theophyllines" & J. of Med Chem., 1966, Vol. 9(4), pgs. 500-506	<input type="checkbox"/>
33	STN Intl, CAPLUS Accession No. 1966:35888, Doc No. 64:35888, Dietz et al., "Synthesis of some 8-alkylthio-2-thiotheophyllines and 8-alkylthio-6-thiotheophyllines" & J. of Med Chem., 1966, Vol. 9(1), pg. 160	<input type="checkbox"/>
34	STN Intl CAPLUS Accession No. 1974:82889, No. 80:82889, Reichman, Uri et al., "Tautomerism, ionization and methylation of 2(methylthio)- and 2,8-bis(methyl-thio)hypoxanthines" & J. of the Chem. Soc., Perkin Transactions 1: Organic & BioOrganic Chem, 1972-1999, (22), 2647-55, 1973	<input type="checkbox"/>
35	STN Intl, File CAPLUS Accession No. 1984:630460, Doc No. 101:230460, Talukdar, P.B. et al., "Studies on ring-fused mesoionic thiazolo(3,2-a) imidazolo(4,5-d)pyrimidine derivatives," & Indian J. of Chem, Section B: Organic Chem. Including Medicinal Chem, 23B(4), pgs. 316-320, 1984	<input type="checkbox"/>
36	STN Intl, file Registry, "2H-Purin-2-one, 1,3,6,7-tetrahydro-8-(methylthio)-6-thioxo-(9CI) Reg No. 500336-85-6	<input type="checkbox"/>
37	STN Intl, file Registry, "2-H-Purin-2-one, 1,3,6,7-tetrahydro-8-(propylthio)-6-thioxo-, sodium salt (9CI)" Reg No. 5784-48-5	<input type="checkbox"/>
38	STN Intl, file Registry, "1H-Purine-2,6-dithione, 3,7-dihydro-1,3-dimethyl-8-(methylthio)-, sodium salt (9CI)" Reg No. 5779-07-7	<input type="checkbox"/>
39	STN Intl, file Registry, "2h-Purin-2-one, 8-[(1-ethylbutyl)thio]-1,3,6,7-tetrahydro-1,3-dimethyl-6-thioxo-, sodium salt (9CI)", Reg No. 5779-06-6	<input type="checkbox"/>
40	STN printout for Registry No. 582-33-2: 3-Aminobenzoic acid ethyl ester	<input type="checkbox"/>
41	CAPLUS 1986:626214, English abstract for CN 1013676	<input type="checkbox"/>
42	Non-final Office Action issued for U.S. patent application No. 10/476,999 on October 31, 2005 (10/476,999 issued September 19, 2006 as U.S. patent no. 7,108,997, which was cited on Form SB08a submitted July 23, 2007)	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10511537
Filing Date	2004-10-15
First Named Inventor	Hanson
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	100647-1P US

43	Advisory Action issued for 10/275,824 on May 22, 2007 (10/275,824, which is now abandoned, published as U.S. publication No. 2004-0029871, which is cited hereinabove)	<input type="checkbox"/>
44	Copy of final Office Action issued for 10/275,824 on February 8, 2007 (10/275,824, which is now abandoned, published as U.S. publication No. 2004-0029871, which is cited hereinabove)	<input type="checkbox"/>
45	Non-final Office Action issued for 10/275,824 on June 19, 2006 (10/275,824, which is now abandoned, published as U.S. publication No. 2004-0029871, which is cited hereinabove)	<input type="checkbox"/>
46	Advisory Action issued for 10/275,824 on March 15, 2006 (10/275,824, which is now abandoned, published as U.S. publication No. 2004-0029871, which is cited hereinabove)	<input type="checkbox"/>
47	Final Office Action issued for 10/275,824 on November 30, 2005 (10/275,824, which is now abandoned, published as U.S. publication No. 2004-0029871, which is cited hereinabove)	<input type="checkbox"/>
48	Non-final Office Action issued for 10/275, 824 on June 17, 2005 (10/275,824, which is now abandoned, published as U.S. publication No. 2004-0029871, which is cited hereinabove)	<input type="checkbox"/>
49	U.S. Application Serial No. 11/756,967, Attorney Docket No. 102288-2 US, filed June 1, 2007	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10511537
Filing Date	2004-10-15
First Named Inventor	Hanson
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	100647-1P US

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Jacqueline M. Cohen/	Date (YYYY-MM-DD)	2007-10-30
Name/Print	Jacqueline M. Cohen	Registration Number	51574

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.